• 1
    Miller BA, Kolonel LN, Bernstein L, et al. Racial/ethnic patterns of cancer in the United States 1988–92. NIH Publication No. 96-4104. Bethesda, MD: National Cancer Institute, 1996.
  • 2
    Juhász M, Nitsche B, Malfertheiner P, Ebert MPA. Implications of growth factor alterations in the treatment of pancreatic cancer. Mol Cancer 2003; 2: 5.
  • 3
    Dong M, Nio Y, Tamura K, et al. Ki-ras point mutation and p53 expression in human pancreatic cancer: a comparative study among Chinese, Japanese, and Western patients. Cancer Epidemiol Biomarkers Prev 2000; 9: 27984.
  • 4
    Hewett-Emmet D. In: Chegwidden WR, Carter ND, Edwards Y, eds. The Carbonic Anhydrases: New Horizon. Basel: Birkhauser, Verlag, 2000.
  • 5
    Nishimori I, Fujikawa-Adachi K, Onishi S, Hollingsworth MA. Carbonic anhydrase in human pancreas: hypotheses for the pathophysiological roles of CA isozymes. Ann NY Acad Sci 1999; 880: 516.
  • 6
    Pastorek J, Pastorekova S, Callebaut I, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 1994; 9: 287788.
  • 7
    Saarnio J, Parkkila S, Parkkila AK, et al. Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity. J Histochem Cytochem 1998; 46: 497504.
  • 8
    Pastorekova S, Parkkila S, Parkkila AK, et al. Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 1997; 112: 398408.
  • 9
    Uemura H, Nakagawa Y, Yoshida K, et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 1999; 81: 7416.
  • 10
    Liao SY, Aurelio ON, Jan K, Zavada J, Stanbridge EJ. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 1997; 57: 282731.
  • 11
    McKiernan JM, Buttyan R, Bander NH, et al. Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma. Cancer Res 1997; 57: 23625.
  • 12
    Murakami Y, Kanda K, Tsuji M, Kanayama H, Kagawa S. MN/CA9 gene expression as a potential biomarker in renal cell carcinoma. BJU Int 1999; 83: 7437.
  • 13
    Brewer CA, Liao SY, Wilczynski SP, et al. A study of biomarkers in cervical carcinoma and clinical correlation of the novel biomarker MN. Gynecol Oncol 1996; 63: 33744.
  • 14
    Liao SY, Brewer C, Zavada J, et al. Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol 1994; 145: 598609.
  • 15
    Loncaster JA, Harris AL, Davidson SE, et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001; 61: 63949.
  • 16
    Zavada J, Zavadova Z, Pastorekova S, Ciampor F, Pastorek J, Zelnik V. Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer 1993; 54: 26874.
  • 17
    Saarnio J, Parkkila S, Parkkila AK, et al. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase. MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol 1998; 153: 27985.
  • 18
    Turner JR, Odze RD, Crum CP, Resnick MB. MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker. Hum Pathol 1997; 28: 7404.
  • 19
    Uemura H, Kitagana H, Hirso Y, Okajama E, DeBruyne F, Coaterwijk E. Expression of tumour-associated antigen MN/G250 in urologic carcinoma: potential therapeutic target. J Urol 1997; 157: 377.
  • 20
    Vermylen P, Roufosse C, Burny A, et al. Carbonic anhydrase IX antigen differentiates between preneoplastic and malignant lesions in non-small cell lung carcinoma. Eur Respir J 1999; 14: 80611.
  • 21
    Beasley NJ, Wykoff CC, Watson PH, et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 2001; 61: 52627.
  • 22
    Ivanov S, Liao SY, Ivanova A, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001; 158: 90519.
  • 23
    Martin L, Green B, Renshaw C, et al. Examining the technique of angiogenesis assessment in invasive breast cancer. Br J Cancer 1997; 76: 104654.
  • 24
    Schoell WMJ, Pieber D, Reich O, et al. Tumor angiogenesis as a prognostic factor in ovarian carcinoma. Cancer 1997; 80: 225762.
  • 25
    Wagatsuma S, Konno R, Sato S, Yajima A. Tumor angiogenesis, hepatocyte growth factor, and c-met expression in endometrial carcinoma. Cancer 1998; 82: 52030.
  • 26
    Kasper HU, Ebert M, Malfertheiner P, Roessner A, Kirkpatrick CJ, Wolf HK. Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density. Virchows Arch 2001; 438: 11620.
  • 27
    Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 2001; 7: 3399403.
  • 28
    Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001; 61: 79928.
  • 29
    Sobin LH, Wittekind Ch. TNM Classification of Malignant Tumours, 6th edn. New York, NY: Wiley Publishers, 2002.
  • 30
    Pastorekova S, Zavadova Z, Kostal M, Babusikova O, Zavada J. A novel quasi-viral agent, MaTu, is a two-component system. Virology 1992; 187: 6206.
  • 31
    Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Meth 1992; 152: 23744.
  • 32
    Kawai A, Noguchi M, Beppu Y, et al. Nuclear immunoreaction of p53 protein in soft tissue sarcomas. Cancer 1994; 73: 2499505.
  • 33
    Vermeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumors: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996; 32: 247484.
  • 34
    Ebert M, Yokoyama M, Kobrin MS, et al. Induction and expression of amphiregulin in human pancreatic cancer. Cancer Res 1994; 54: 395962.
  • 35
    Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000; 60: 707583.
  • 36
    Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996; 56: 9413.
  • 37
    Kivelä AJ, Parkkila S, Saarnio J, et al. Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours. Histochem Cell Biol 2000; 114: 197204.
  • 38
    Bartosova M, Parkkila S, Pohlodek K, et al. Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2. J Pathol 2000; 197: 31421.
  • 39
    Chia SK, Wykoff CC, Watson PH, et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 2001; 19: 36608.
  • 40
    Yokoyama M, Yamanaka Y, Friess H, Buchler M, Korc M. p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res 1994; 14: 247783.
  • 41
    Lieskovska J, Kaluzova M, Opavsky R, et al. Up-regulation of p53 by antisense expression of HPV18 E6 oncogene does not influence the level of MN/CA IX tumour-associated protein in HeLa cervical carcinoma cells. Int J Oncol 1998; 13: 10816.
  • 42
    Niedergethmann M, Hildenbrand R, Wostbrock R, et al. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 2002; 25: 1229.
  • 43
    Linder S, Blasjo M, Von Rosen A, et al. Pattern of distribution and prognostic value of angiogenesis in pancreatic duct carcinoma: a semiquantitative immunohistochemical study of 45 patients. Pancreas 2001; 22: 2407.
  • 44
    Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors — part 94. 1,3,4–thiadiazole-2-sulfonamide derivatives as antitumor agents? Eur J Med Chem 2000; 35: 86774.
  • 45
    Wingo T, Tu C, Laipis PJ, et al. The catalytic properties of human carbonic anhydrase IX. Biochem Biophys Res Commun 2001; 288: 6669.
  • 46
    Parkkila S, Rajaniemi H, Parkkila AK, et al. Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc Natl Acad Sci USA 2000; 97: 22204.